



## OPEN ACCESS

EDITED AND REVIEWED BY  
Jozsef Soki,  
University of Szeged, Hungary

\*CORRESPONDENCE  
Yuanhong Xu  
xyhong1964@163.com  
Ling Tang  
tling@mail.ustc.edu.cn

†These authors have contributed  
equally to this work

SPECIALTY SECTION  
This article was submitted to  
Infectious Diseases – Surveillance,  
Prevention and Treatment,  
a section of the journal  
Frontiers in Public Health

RECEIVED 27 September 2022  
ACCEPTED 03 October 2022  
PUBLISHED 04 November 2022

CITATION  
Li Y, Liu T, Shi C, Wang B, Li T, Huang Y,  
Xu Y and Tang L (2022) Corrigendum:  
Epidemiological, clinical, and  
laboratory features of patients infected  
with *Elizabethkingia meningoseptica* at  
a tertiary hospital in Hefei City, China.  
*Front. Public Health* 10:1054878.  
doi: 10.3389/fpubh.2022.1054878

COPYRIGHT  
© 2022 Li, Liu, Shi, Wang, Li, Huang,  
Xu and Tang. This is an open-access  
article distributed under the terms of  
the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution  
or reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Corrigendum: Epidemiological, clinical, and laboratory features of patients infected with *Elizabethkingia meningoseptica* at a tertiary hospital in Hefei City, China

Yajuan Li<sup>†</sup>, Tingting Liu<sup>†</sup>, Cuixiao Shi, Bo Wang, Tingting Li,  
Ying Huang, Yuanhong Xu\* and Ling Tang\*

Department of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China

## KEYWORDS

*Elizabethkingia meningoseptica*, infection, clinical and laboratory features, fever, hepatic disease

## A corrigendum on

Epidemiological, clinical, and laboratory features of patients infected with *Elizabethkingia meningoseptica* at a tertiary hospital in Hefei City, China

by Li, Y., Liu, T., Shi, C., Wang, B., Li, T., Huang, Y., Xu, Y., and Tang, L. (2022). *Front. Public Health* 10:964046. doi: 10.3389/fpubh.2022.964046

In the published article, there was an error in [Table 4](#) “*In vitro* of drug susceptibility results of patients infected with *E. meningoseptica* ( $N = 24$ )” as published. We are sorry for the percentage error, which is due to format conversion in the manuscript modification. This does not influence the *P*-value and the conclusion of the article. In the survival group, 85.7% of 14 strains was susceptible to piperacillin/tazobactam and 92.9% of 14 strains was susceptible to cotrimoxazole. In the death group, 70% of 10 strains was susceptible to levofloxacin and 60% of 10 strains was susceptible to piperacillin/tazobactam. The intermediate resistance of strains in the death group to levofloxacin was 10%. The resistance rates of all strains to levofloxacin and piperacillin/tazobactam were 20.8 and 8.3%, respectively. The resistance rate of strains

in the survival group to amikacin, aztreonam, imipenem, and tobramycin was 92.9%. The resistance rate of strains in the death group to levofloxacin was 20%. The corrected [Table 4](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 4 The original "TABLE 4 *In vitro* of drug susceptibility results of patients infected with *E. meningoseptica* (N = 24)."

Variable	Susceptible				Intermediate				Resistant			
	Total (N = 24)	Survival (n = 14)	Death (n = 10)	P-value	Total (N = 24)	Survival (n = 14)	Death (n = 10)	P-value	Total (N = 24)	Survival (n = 14)	Death (n = 10)	P-value
Ceftazidime	1 (4.2)	1 (7.1)	0 (0.0)	1.000	1 (4.2)	1 (7.1)	0 (0.0)	1.000	22 (91.7)	12 (85.7)	10 (100.0)	0.493
Amikacin	0 (0.0)	0 (0.0)	0 (0.0)	-	1 (4.2)	1 (7.1)	0 (0.0)	1.000	23 (95.8)	13 (93.9)	10 (100.0)	1.000
Aztreonam	1 (4.2)	1 (7.1)	0 (0.0)	1.000	0 (0.0)	0 (0.0)	0 (0.0)	-	23 (95.8)	13 (93.9)	10 (100.0)	1.000
Cefazolin	0 (0.0)	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	0 (0.0)	-	24 (100.0)	14 (100.0)	10 (100.0)	1.000
Cefepime	1 (4.2)	1 (7.1)	0 (0.0)	1.000	1 (4.2)	1 (7.1)	0 (0.0)	1.000	22 (91.7)	12 (85.7)	10 (100.0)	0.493
Ceftriaxone	1 (4.2)	1 (7.1)	0 (0.0)	1.000	1 (4.2)	1 (7.1)	0 (0.0)	1.000	22 (91.7)	12 (85.7)	10 (100.0)	0.493
Ciprofloxacin	14 (58.3)	6 (42.9)	8 (80.0)	0.104	3 (12.5)	3 (21.4)	0 (0.0)	0.239	7 (29.2)	5 (35.7)	2 (20.0)	0.653
Gentamycin	1 (4.2)	0 (0.0)	1 (10.0)	0.417	5 (20.8)	2 (14.3)	3 (30.0)	0.615	18 (75.0)	12 (85.7)	6 (60.0)	0.192
Imipenem	1 (4.2)	1 (7.1)	0 (0.0)	1.000	0 (0.0)	0 (0.0)	0 (0.0)	-	23 (95.8)	13 (93.9)	10 (100.0)	1.000
Levofloxacin	18 (75.0)	11 (78.6)	7 (77.8)	0.665	1 (4.2)	0 (0.0)	1 (11.1)	0.417	5 (16.6)	3 (21.4)	2 (22.2)	1.000
Piperacillin/tazobactam	18 (75.0)	12 (92.3)	6 (66.7)	0.192	4 (16.7)	1 (7.1)	3 (30.0)	0.272	2 (8.4)	1 (7.1)	1 (10.0)	1.000
Tobramycin	1 (4.2)	1 (7.1)	0 (0.0)	1.000	0 (0.0)	0 (0.0)	0 (0.0)	-	23 (95.8)	13 (93.9)	10 (100.0)	1.000
Cotrimoxazole	21 (87.5)	13 (93.9)	8 (80.0)	0.550	0 (0.0)	0 (0.0)	0 (0.0)	-	3 (12.5)	1 (7.1)	2 (20.0)	0.550

TABLE 4 The corrected "TABLE 4 *In vitro* of drug susceptibility results of patients infected with *E. meningoseptica* (N = 24)."

Variable	Susceptible				Intermediate				Resistant			
	Total (N = 24)	Survival (n = 14)	Death (n = 10)	P-value	Total (N = 24)	Survival (n = 14)	Death (n = 10)	P-value	Total (N = 24)	Survival (n = 14)	Death (n = 10)	P-value
Ceftazidime	1 (4.2)	1 (7.1)	0 (0.0)	1.000	1 (4.2)	1 (7.1)	0 (0.0)	1.000	22 (91.7)	12 (85.7)	10 (100.0)	0.493
Amikacin	0 (0.0)	0 (0.0)	0 (0.0)	-	1 (4.2)	1 (7.1)	0 (0.0)	1.000	23 (95.8)	13 (92.9)	10 (100.0)	1.000
Aztreonam	1 (4.2)	1 (7.1)	0 (0.0)	1.000	0 (0.0)	0 (0.0)	0 (0.0)	-	23 (95.8)	13 (92.9)	10 (100.0)	1.000
Cefazolin	0 (0.0)	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	0 (0.0)	-	24 (100.0)	14 (100.0)	10 (100.0)	1.000
Cefepime	1 (4.2)	1 (7.1)	0 (0.0)	1.000	1 (4.2)	1 (7.1)	0 (0.0)	1.000	22 (91.7)	12 (85.7)	10 (100.0)	0.493
Ceftriaxone	1 (4.2)	1 (7.1)	0 (0.0)	1.000	1 (4.2)	1 (7.1)	0 (0.0)	1.000	22 (91.7)	12 (85.7)	10 (100.0)	0.493
Ciprofloxacin	14 (58.3)	6 (42.9)	8 (80.0)	0.104	3 (12.5)	3 (21.4)	0 (0.0)	0.239	7 (29.2)	5 (35.7)	2 (20.0)	0.653
Gentamycin	1 (4.2)	0 (0.0)	1 (10.0)	0.417	5 (20.8)	2 (14.3)	3 (30.0)	0.615	18 (75.0)	12 (85.7)	6 (60.0)	0.192
Imipenem	1 (4.2)	1 (7.1)	0 (0.0)	1.000	0 (0.0)	0 (0.0)	0 (0.0)	-	23 (95.8)	13 (92.9)	10 (100.0)	1.000
Levofloxacin	18 (75.0)	11 (78.6)	7 (70.0)	0.665	1 (4.2)	0 (0.0)	1 (10.0)	0.417	5 (20.8)	3 (21.4)	2 (20.0)	1.000
Piperacillin/tazobactam	18 (75.0)	12 (85.7)	6 (60.0)	0.192	4 (16.7)	1 (7.1)	3 (30.0)	0.272	2 (8.3)	1 (7.1)	1 (10.0)	1.000
Tobramycin	1 (4.2)	1 (7.1)	0 (0.0)	1.000	0 (0.0)	0 (0.0)	0 (0.0)	-	23 (95.8)	13 (92.9)	10 (100.0)	1.000
Cotrimoxazole	21 (87.5)	13 (92.9)	8 (80.0)	0.550	0 (0.0)	0 (0.0)	0 (0.0)	-	3 (12.5)	1 (7.1)	2 (20.0)	0.550